Integrated molecular and clinical analysis of BRAF-mutant glioma in adults

13Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BRAF mutations are a significant driver of disease in pediatric low-grade glioma, but the implications of BRAF alterations on the clinical course and treatment response in adult glioma remain unclear. Here, we characterize a multi-institutional cohort of more than 300 patients (>200 adults) with BRAF-mutated glioma using clinical, pathological/molecular, and outcome data. We observed that adult and pediatric BRAF-mutant gliomas harbor distinct clinical and molecular features, with a higher prevalence of BRAFV600E (Class I) and BRAF fusions in pediatric tumors. BRAFV600E alterations were associated with improved survival in adults with glioma overall, though not in glioblastoma. Other genomic alterations observed within functional classes were consistent with the putative roles of those BRAF mutation classes in glioma pathogenesis. In our adult cohort, BRAFV600E alterations conferred sensitivity to targeted therapies. Overall, this large cohort of BRAF-altered adult gliomas demonstrates a broad range of molecular alterations with implications for treatment sensitivity and survival.

Cite

CITATION STYLE

APA

Schreck, K. C., Langat, P., Bhave, V. M., Li, T., Woodward, E., Pratilas, C. A., … Bi, W. L. (2023). Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. Npj Precision Oncology, 7(1). https://doi.org/10.1038/s41698-023-00359-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free